Please login to the form below

Not currently logged in
Email:
Password:

biosimilars

This page shows the latest biosimilars news and features for those working in and with pharma, biotech and healthcare.

Alexion eyes Soliris combo with $930m deal to buy Achillion

Alexion eyes Soliris combo with $930m deal to buy Achillion

The drug currently accounts for more than 80% of Alexion’s sales, but is facing the threat of biosimilar competition. ... While Alexion recently claimed a patent extension in the US until 2027, that is subject to a challenge by Amgen that – if

Latest news

More from news
Approximately 135 fully matching, plus 325 partially matching documents found.

Latest Intelligence

  • The Golden Goose The Golden Goose

    Biosimilar fail. Another stumbling block has been our over-reliance on market-based solutions to this problem, ie, generics. ... The thinking was at that time we’d solved the biosimilar problem, and here we are nine years later saying, no, we haven’t.

  • Transitions in healthcare Transitions in healthcare

    Switching from an originator biologic to a cheaper biosimilar. These are all examples of the kind of treatment transitions patients experience that can be supported by Patient Support Programmes.

  • It’s not the end of the world, is it? It’s not the end of the world, is it?

    Whether we market branded products that offer no real superiority over generics, biosimilars or me-toos or we sell innovative products whose price differential is not financially justified, much of what

  • Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019 Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

    It will compete with numerous treatment modalities, including entrenched biological agents and biosimilar biologicals.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    The world’s biggest selling drug, Humira, lost its market exclusivity in Europe to biosimilar competition in 2018, and AbbVie is well aware of the impending US patent expiry in 2022. ... Finally, 2019 will see a rapid increase in the uptake of Humira

More from intelligence
Approximately 11 fully matching, plus 57 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 15 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 13 fully matching, plus 23 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...
What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...

Infographics